American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...
LifeVantage Corporation ® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the completion of an ...
Zacks.com on MSN3h
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?McKesson Corporation MCK is scheduled to report third-quarter fiscal 2025 results on Feb. 5, after market close. The company ...
"Don’t treat the doctor's office like an assignment. Think of it like BODY MAINTENANCE. You’d do it for your car, right?" ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback